Search the Newsreel

Kinetik Holdings Inc. $KNTK Shares Sold by Pacer Advisors Inc.

Birchbrook Inc. Trims Stock Position in Fortinet, Inc. $FTNT

Birchbrook Inc. significantly reduced its stake in Fortinet, Inc. by 48.6% in the second quarter, selling 7,709 shares and retaining 8,161 shares valued at $1,254,000. Despite this, other institutional investors have increased their holdings in Fortinet, with hedge funds and institutional investors collectively owning …

Intel Secures Key Deal with Fortinet for Cybersecurity Chips

Intel's foundry business has secured a significant deal with Fortinet to manufacture its next-generation Security Processor 6, marking Intel's entry into the cybersecurity chip sector. This partnership reduces Fortinet's reliance on TSMC, challenges TSMC's market dominance, and could attract more clients to Intel's foundry. …

Kinetic Development Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2026

Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Did TriNet’s Higher-Earnings-But-Lower-Revenue Quarter Just Shift TriNet Group’s (TNET) Investment Narrative?

TriNet Group (TNET) reported higher net income and diluted EPS in Q2 2026 despite lower revenue, leading to raised full-year guidance for both revenue and EPS. This shift suggests stronger profitability expectations and management confidence, reinforced by dividend increases. However, the investment narrative still …

Fortinet (FTNT) Lifted 2026 Guidance, Is The Stock Now Too Expensive?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Fortinet (FTNT) drew fresh investor attention after reporting second quarter 2026 results and issuing new guidance, including a full year 2026 revenue outlook …

Cytokinetics (NASDAQ:CYTK) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Kinetik Q2 Earnings Call Highlights

Key Points Interested in Kinetik Holdings Inc.? Here are five stocks we like better. Kinetik reported record second-quarter results, including $281 million in Adjusted EBITDA, $195 million in distributable cash flow and $105 million in free cash flow. Midstream Logistics EBITDA increased 35% year …

Jim Cramer Favors Fortinet (FTNT) Alongside CrowdStrike (CRWD) and Palo Alto (PANW)

During the lightning round on the August 5 episode of CNBC's Mad Money, a caller asked a question regarding Fortinet, Inc. (NASDAQ:FTNT). and Cramer responded: Okay, we just had a little kind of a discussion. Fortinet's good, by the way. We had a little …

Cytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval

Cytokinetics (CYTK) stock has shown strong returns over five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. Despite recent UK approval for MYQORZO, the stock's high price-to-book ratio is not a reliable indicator due to the company's development-heavy …

Will Kinetik’s Q2 2026 Earnings Beat and Revenue Surge Change Kinetik Holdings' (KNTK) Narrative?

Fabrinet $FN Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Fabrinet (NYSE:FN) by 130.8% in the first quarter, now owning 7,039 shares valued at $3.67 million. Institutional investors collectively hold 97.38% of the company's stock. Fabrinet, trading at $561.84 with a market cap of $20.13 …

Beacon Investment Advisory Services Inc. Sells 10,085 Shares of Fortinet, Inc. $FTNT

Beacon Investment Advisory Services Inc. decreased its stake in Fortinet, Inc. (NASDAQ:FTNT) by 4.2% in the second quarter, selling 10,085 shares and retaining 231,189 shares valued at $35.5 million. Fortinet, a multinational cybersecurity company, has a consensus "Hold" rating from analysts with a target …

Wall Street Zen Downgrades Cytokinetics (NASDAQ:CYTK) to Sell

Wall Street Zen downgraded Cytokinetics (NASDAQ:CYTK) to a "sell" rating from "hold," despite the broader analyst consensus remaining a "Moderate Buy." This downgrade follows the biopharmaceutical company's quarterly results, which saw revenue decline 57.1% year-over-year and substantial losses, although reported revenue and EPS still …

Fortinet (FTNT) Stock Could Be 12% Overvalued On Raised 2026 Outlook

Kinetik (NYSE:KNTK) Stock Rating Upgraded by Wall Street Zen

Amundi Purchases 5,299 Shares of Fabrinet $FN

Amundi increased its stake in Fabrinet (NYSE:FN) by 301.1% in the first quarter, acquiring 5,299 additional shares, bringing its total holdings to 7,059 shares valued at $3.68 million. Fabrinet reported strong quarterly earnings with an EPS of $3.72 and revenue of $1.21 billion, surpassing …

Kinetik Holdings director ISQ Global Fund II GP LLC sells $13.3m shares

ISQ Global Fund II GP LLC, a director and 10% owner of Kinetik Holdings Inc. (KNTK), sold approximately $13.3 million worth of Class A Common Stock between August 3 and August 7, 2026, at prices ranging from $50.0416 to $51.0219 per share. These sales …

Kinetik Holdings Inc. (NYSE: KNTK) insiders sell 264K shares near $50

Entities associated with I Squared Capital, identified as ten percent owners of Kinetik Holdings Inc. (NYSE: KNTK), indirectly sold a total of 264,074 shares of Class A Common Stock between August 3 and August 7, 2026. The sales were conducted through Buzzard Midstream LLC …

Kinetik Holdings (NYSE: KNTK) plans sale of 264,074 Class A shares via Goldman Sachs

Kinetik Holdings Inc. (NYSE: KNTK) has filed a Form 144 indicating a planned sale of 264,074 Class A Common Stock shares through Goldman Sachs & Co. LLC on or after August 3, 2026. These shares, valued at approximately $12.99 million, were acquired on April …

Citizens raises Cytokinetics stock price target on strong launch

Citizens has raised its price target for Cytokinetics (NASDAQ:CYTK) to $110 from $105, maintaining a Market Outperform rating, citing the strong launch of MYQORZO and ongoing pipeline development. The company's stock has surged 131% over the past year, currently trading at $81.37, and its …

Crinetics Pharmaceuticals (NASDAQ: CRNX) sees 1.4% stake reported by FMR LLC

FMR LLC and Abigail P. Johnson have reported an amended passive investment disclosure for Crinetics Pharmaceuticals (CRNX) via a Schedule 13G/A filing. FMR LLC holds beneficial ownership of 1,439,890.88 shares, representing 1.4% of the common stock outstanding, with nearly all shares holding sole voting …

Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Glenmede Trust Co. NA

Glenmede Trust Co. NA increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 72.6% in the first quarter, now holding 29,245 shares valued at $1.06 million. Despite some insider selling, institutional investors own 98.51% of the company. Crinetics Pharmaceuticals reported better-than-expected Q1 earnings with a …

Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses

Cytokinetics (CYTK) saw its shares fall 6% despite early success with its new cardiomyopathy drug, MYQORZO, which generated $25.3 million in net product revenue. The company posted a significant net loss of $198.8 million in Q2 2026, widening from the previous year, as heavy …

Fortinet, Inc. $FTNT Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP significantly reduced its stake in Fortinet (NASDAQ:FTNT) by 96.6% in the second quarter, selling 1.47 million shares. Despite this, institutional investors still hold 83.71% of the company's stock. Fortinet reported strong quarterly earnings, beating estimates with $0.90 EPS and a …

TriNet Group, Inc. (NYSE:TNET) Given Average Recommendation of "Hold" by Brokerages

TriNet Group, Inc. (NYSE:TNET) has received an average "Hold" recommendation from seven brokerages, with an average 12-month price target of $56.80. Despite beating quarterly earnings expectations with $1.55 EPS on $1.18 billion revenue and providing strong fiscal 2026 EPS guidance, the stock's shares have …

Quantinno Capital Management LP Acquires 123,717 Shares of TriNet Group, Inc. $TNET

Quantinno Capital Management LP significantly increased its holdings in TriNet Group, Inc. (NYSE:TNET) by 1,052.6%, adding 123,717 shares to now own 135,470 shares valued at $4.94 million. Institutional investors collectively own 96.81% of TNET, while the company recently reported strong quarterly earnings, beating estimates …

Janus Henderson Group PLC Decreases Stock Holdings in Fortinet, Inc. $FTNT

Janus Henderson Group PLC significantly reduced its stake in Fortinet, Inc. by 60.3% in the first quarter, selling 115,815 shares, though institutional investors still hold a substantial 83.71% of FTNT. Despite this reduction and mixed analyst sentiment (average price target below current price), Fortinet …

Kinetik Holdings Inc (KNTK) Stock News Today

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the market for cystic fibrosis (CF) medicines since it earned approval for its first drug in this niche in 2012. To this day, most of the company's revenue comes from its CF franchise. In the second quarter, Vertex …

Network security platform and AI governance at Fortinet

Fortinet is addressing the complexities of the AI era by advocating for a unified network security platform that integrates networking and security into a single, consistently governed fabric. This strategy, dubbed the "SASE Firewall," converges secure access service edge and next-generation firewall capabilities. The …

Cytokinetics (NASDAQ:CYTK) Shares Down 6.6% - Here's What Happened

Cytokinetics (NASDAQ:CYTK) shares fell 6.6% despite reporting Q2 2026 revenues and EPS that beat analyst expectations. The stock decline was influenced by a significant year-over-year revenue decrease, widening losses, substantial operating cash outflow, and ongoing insider selling. Despite these concerns, Wall Street analysts maintain …

Cytokinetics, Incorporated Stock 12‑Month Price Target Cut to $107.65, Implies 32% Upside

Cytokinetics, Incorporated's average 12-month stock price target has been slightly cut from $108.47 to $107.65 by 20 analysts, still implying a 32% potential upside from its August 6 closing price. The consensus rating remains a "Buy" across 23 covering analysts, with 21 buys and …

CYTOKINETICS INC Q2 2026: Revenue $28.6M, EPS $(1.50) — 10-Q Summary

CYTOKINETICS INC (CYTK) reported Q2 2026 results with revenue of $28.6 million, primarily driven by the first commercial sales of MYQORZO, which generated $25.3 million. The company posted a net loss of $198.8 million and diluted EPS of $(1.50), both wider than the previous …